Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Sumitra D MitraDepartment of Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.ORCID 0000-0001-7239-4000
Maulin SonejiDepartment of Medicine, Division of Infectious Diseases, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.ORCID 0000-0003-4333-5233
Christopher M R AxlineDepartment of Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.ORCID 0009-0002-8392-5991
Hillary S HaydenDepartments of Microbiology and Medicine, University of Washington, Seattle, Washington, USA.
Matthew C RadeyDepartments of Microbiology and Medicine, University of Washington, Seattle, Washington, USA.
Cara M ForsbergDepartments of Microbiology and Medicine, University of Washington, Seattle, Washington, USA.
Egon A OzerDepartment of Medicine, Division of Infectious Diseases, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
Daniel J WolterDepartments of Pediatrics, University of Washington, Seattle, Washington, USA.
Christopher E PopeDepartments of Pediatrics, University of Washington, Seattle, Washington, USA.
Jane BurnsDepartments of Pediatrics, University of Washington, Seattle, Washington, USA.
Nicole Mayer-HamblettSeattle Children's Research Institute, Seattle, Washington, USA.
Pradeep SinghDepartments of Microbiology and Medicine, University of Washington, Seattle, Washington, USA.
Alan R HauserDepartment of Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.ORCID 0000-0003-4596-7939
Funding
Transform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0M
Translational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI PRADEEP k SINGH · 2010 to 2026
$21.4M
Early Antipseudomonal Therapy in Cystic FibrosisU01HL080310 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI RAMSEY, BONNIE W · 2004 to 2008
$6.5M
Population Analysis of Pseudomonas aeruginosa VirulenceR01AI118257 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HAUSER, ALAN R · 2016 to 2025
$4.9M
Field Study to Understand Progression of Chronic Airway InfectionR01HL148274 · NHLBI · UNIVERSITY OF WASHINGTON · PI EMOND, MARY J, SINGH, PRADEEP K · 2019 to 2022
$2.9M
Translational Research Training in Infectious DiseasesT32AI095207 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Claudia A Hawkins, Jennie H Kwon · 2012 to 2026
$2.2M
Prevalence, Consequences and Mechanisms of Antibiotic Heteroresistance in Cystic FibrosisR01HL160710 · NHLBI · UNIVERSITY OF WASHINGTON · PI SINGH, PRADEEP K · 2022 to 2025
$2.2M
Pseudomonas aeruginosa Adaptation During Early CF Airway Infection and TreatmentR01HL098084 · NHLBI · UNIVERSITY OF WASHINGTON · PI HOFFMAN, LUCAS R · 2009 to 2012
$1.6M
Patient-oriented microbiome and advanced culture approaches to identifying the microbial determinants of chronic pediatric diseaseK24HL141669 · NHLBI · UNIVERSITY OF WASHINGTON · PI Lucas R Hoffman · 2018 to 2026
$929k
Pseudomonas Genomic Signatures Associated With Persistence in Cystic FibrosisR21HL129930 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HAMBLETT, NICOLE MAYER, HAUSER, ALAN R · 2015 to 2016
$438k
High-Risk Clones of Pseudomonas aeruginosaR21AI164254 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HAUSER, ALAN R · 2021 to 2022
$431k
Cystic Fibrosis Foundation Center for Cystic Fibrosis MicrobiologyCystic Fibrosis Foundation EPIC0K0Cystic Fibrosis Foundation HAUSER1510Cystic Fibrosis Foundation HOFFMA20Y2Cystic Fibrosis Foundation SINGH15UOCystic Fibrosis Foundation SINGH19R0National Heart Lung and Blood InstituteNational Institute for Digestive Disorders and Kidney U01-HL080310National Institute of Health K24 AI04831National Institute of Health P30 DK 089507National Institute of Health R01HL098084National Institute of Health R01HL148274National Institute of Health R21AI164254NCATS NIH HHS UL1 TR002319NHLBI NIH HHS K24 HL141669NHLBI NIH HHS R01 HL098084NHLBI NIH HHS R01 HL148274NHLBI NIH HHS R01 HL160710NHLBI NIH HHS R21 HL129930NHLBI NIH HHS U01 HL080310NIAID NIH HHS R01 AI118257NIAID NIH HHS R21 AI164254NIAID NIH HHS T32 AI095207NIDDK NIH HHS P30 DK089507
6 · The paper itself
Abstract
backgroundRelatively little is known about Pseudomonas aeruginosa lineages during early infection in individuals with cystic fibrosis (CF). The Early Pseudomonas Infection Control Clinical Trial (EPIC-CT), which treated individuals with CF and newly detected P. aeruginosa infections, presents an ideal opportunity to study this phenomenon.
methodsWe performed whole-genome sequencing on 572 P. aeruginosa isolates from 190 EPIC-CT subjects.
resultsWe identified 203 P. aeruginosa lineages causing newly detected infections near the time of enrollment of these subjects. Twelve subjects were initially infected with more than one P. aeruginosa lineage, and 20 subjects had different PA lineages detected during the follow-up period of the EPIC-CT. Of the 203 lineages causing initial infections, 144 were not detected again by culture and 59 were detected again despite antibiotic therapy. Multilocus sequence typing was as accurate as whole genome single nucleotide variant (SNV) typing in discriminating lineages, but pulsed-field gel electrophoresis inaccurately classified 17 genetically related isolates as distinct. Although subjects were infected for a relatively short time, 23 P. aeruginosa genes acquired nonsynonymous SNVs in at least 2 subjects. Of these, 14 had been previously identified as pathoadaptive, confirming that such mutations can emerge early in CF infections.
conclusionsOur study demonstrates the complexity of early P. aeruginosa infections in people with CF and the potential of these complexities to confound interpretation of antibiotic efficacy studies.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Culture and Adaptation of Pseudomonas aeruginosa During Early Infection in Children With Cystic Fibrosis. · full record | OpenQuestion